摘 要: 多发性骨髓瘤(multiple myeloma, MM)是以骨髓中浆细胞异常增殖为特征的恶性克隆性疾病。尽管近年来MM的治疗有了很大的进展, 但其依旧是不可治愈的疾病。Daratumumab (DARA)是一种人源化抗CD38单克隆抗体, 具有广谱杀伤活性。相关研究证实DARA可以通过多种途径诱导MM细胞的快速死亡。现就CD38分子及DARA作为单药或者联合其他药物治疗复发性、难治性MM患者的临床前实验和临床试验进行综述, 以期说明DARA诱导MM细胞死亡的机制及DARA治疗复发性、难治性MM患者的有效性及安全性, 为DARA治疗复发性、难治性MM患者提出新的研究思路。

Abstract: Multiple myeloma (MM) is a malignant clonal disease that is characterized by proliferation of plasma cells in the bone marrow. Although the therapy for MM has made great process in recent years, it remains an incurable disease. Daratumumab (DARA) is a humanized monoclonal antibody that targets CD38 with broad-spectrum killing activity. Recent studies have shown that DARA induces rapid MM cell death via several mechanisms. Here, the CD38 molecule and DARA as a single agent or in combination with other agents in the treatment of relapsed/refractory MM in preclinical experiments and clinical trials were reviewed to show the mechanisms of DARA in inducing rapid death of MM cells and the efficacy and safety of DARA in the treatment of relapsed/refractory MM patients. It may provide new research directions in the treatment of relapsed/refractory MM patients with DARA.